<DOC>
	<DOCNO>NCT02416258</DOCNO>
	<brief_summary>The purpose study evaluate anti-psoriatic effect LP0113 aerosol spray compare DaivobetÂ® gel , LEO 90100 aerosol foam , betamethasone dipropionate aerosol spray vehicle , calcipotriol aerosol spray vehicle aerosol spray vehicle .</brief_summary>
	<brief_title>A Psoriasis Plaque Test Trial With LP0113 Spray Patients With Psoriasis Vulgaris ( LP0113-1123 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Signed date informed consent obtain Subjects diagnosis psoriasis vulgaris lesion locate arm , leg and/or trunk . The lesion must total size suitable application 6 different product . Age 18 year Outpatients Female subject must either nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus tubal ligation ) , childbearing potential provide confirmed negative pregnancy test prior trial treatment rule pregnancy . Female subject breast feed Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior randomisation : Etanercept within 4 week prior randomisation trial Adalimumab , infliximab within 8 week prior randomisation trial Ustekinumab within 16 week prior randomisation trial Other product within 4 weeks/5 halflives prior randomisation trial ( whichever longer ) Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4week period prior randomisation trial , Subjects use phototherapy within follow time period prior randomisation trial : PUVA : 4 week UVB : 2 week Subjects use one follow topical drug treatment psoriasis within 4 week period prior randomisation trial : Potent potent ( WHO group IIIIV ) corticosteroids Subjects use one follow topical drug treatment psoriasis within 2 week prior randomisation trial : WHO group III corticosteroid ( except use treatment scalp and/or facial psoriasis ) Topical retinoids , Vitamin D analogue , Topical immunomodulators ( e.g . calcineurin inhibitor ) , Tar product , Salicylic acid Subjects use emollient select plaque within 1 week randomisation trial Initiation , expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalarial drug , lithium ACE inhibitor ) within 2 week prior randomisation trial Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>